Claims
- 1. A thieno[2,3-b][1,5]benzodiazepine compound of the formula ##STR31## or a pharmaceutically acceptable acid addition salt thereof, wherein R.sup.1 and R.sup.2 independently represent hydrogen, C.sub.1-4 alkyl, halogen, C.sub.1-4 haloakyl, nitro, amino, C.sub.1-4 alkoxy, C.sub.1-4 alkylthio or a group of the formula --SO.sub.2 N(R.sup.4).sub.2 where R.sup.4 is C.sub.1-4 alkyl; wherein R.sup.6 is hydrogen, phenyl, halophenyl, C.sub.1-4 alkyl, C.sub.1-4 carbalkoxy or --(CH.sub.2).sub.n OH where n is 2 or 3; and wherein the thiophene ring is unsubstituted or is substituted by a C.sub.1-4 alkyl group in the 2-position.
- 2. The compound of claim 1 which is 2-ethyl-7-fluoro-10-(4-methyl-1-piperazinyl)-4H-thieno[2,3-b][1,5]benzodiazepine.
- 3. The compound of claim 1 which is 2-ethyl-7-chloro-10-(4-methyl-1-piperazinyl)-4H-thieno[2,3-b][1,5]benzodiazepine.
- 4. The compound of claim 1 which is 2-ethyl-7-trifluoromethyl-10-(4-methyl-1-piperazinyl)-4H-thieno[2,3-b][1,5]benzodiazepine.
- 5. The compound of claim 1 which is 2-ethyl-7-fluoro-10-(1-piperazinyl)-4H-thieno[2,3-b][1,5]benzodiazepine.
- 6. The compound of claim 1 which is 2-methyl-7-fluoro-10-(4-methyl-1-piperazinyl)-4H-thieno[2,3-b][1,5]benzodiazepine.
- 7. The compound of claim 1 which is 2-isopropyl-7-fluoro-10-(4-methyl-1-piperazinyl)-4H-thieno[2,3-b][1,5]benzodiazepine.
- 8. A method of treating an animal suffering from, or susceptible to, disorder of the CNS, which comprises administering to the animal a chemotherapeutically effective amount of a thieno[2,3-b][1,5]benzodiazepine compound of the formula: ##STR32## or a pharmaceutically-acceptable salt thereof, wherein R.sup.1 and R.sup.2 independently represent hydrogen, C.sub.1-4 alkyl, halogen, C.sub.1-4 haloalkyl, nitro, amino, C.sub.1-4 alkoxy, C.sub.1-4 akylthio or a group of the formula --SO.sub.2 N(R.sup.4).sub.2 where R.sup.4 is C.sub.1-4 alkyl; wherein R.sup.6 is hydrogen, phenyl, halophenyl, C.sub.1-4 alkyl, C.sub.1-4 carbalkoxy or --(CH.sub.2).sub.n OH where n is 2 or 3; and wherein the thiophene ring is unsubstituted or is substituted by a C.sub.1-4 alkyl group in the 2-position.
- 9. The method of claim 8 wherein the thieno[2,3-b][1,5]benzodiazepine is 2-ethyl-7-fluoro-10-(4-methyl-1-piperazinyl)-4H-thieno[2,3-b][1,5]benzodiazepine.
- 10. The method of claim 8 wherein the thieno[2,3-b][1,5]benzodiazepine is 2-ethyl-7-chloro-10-(4-methyl-1-piperazinyl)-4H-thieno[2,3-b][1,5]benzodiazepine.
- 11. The method of claim 8 wherein the thieno[2,3-b][1,5]benzodiazepine is 2-ethyl-7-trifluoromethyl-10-(4-methyl-1-piperazinyl)-4H-thieno[2,3-b][1,5]benzodiazepine.
- 12. The method of claim 8 wherein the thieno[2,3-b][1,5]benzodiazepine is 2-ethyl-7-fluoro-10-(1-piperazinyl)-4H-thieno[2,3-b][1,5]benzodiazepine.
- 13. The method of claim 8 wherein the thieno[2,3-b][1,5]benzodiazepine is 2-methyl-7-fluoro-10-(4-methyl-1-piperazinyl)-4H-thieno[2,3-b][1,5]benzodiazepine.
- 14. The method of claim 8 wherein the thieno[2,3-b][1,5]benzodiazepine is 2-isopropyl-7-fluoro-10-(4-methyl-1-piperazinyl)-4H-thieno[2,3-b][1,5]benzodiazepine.
- 15. A pharmaceutical formulation comprising as an active ingredient a chemotherapeutically effective amount of a thieno[2,3-b][1,5]benzodiazepine compound of the formula: ##STR33## or a pharmaceutically-acceptable salt thereof, wherein R.sup.1 and R.sup.2 independently represent hydrogen, C.sub.1-4 alkyl, halogen, C.sub.1-4 haloalkyl, nitro, amino, C.sub.1-4 alkoxy, C.sub.1-4 alkylthio or a group of the formula --SO.sub.2 H(R.sup.4).sub.2 where R.sup.4 is C.sub.1-4 alkyl; wherein R.sup.6 is hydrogen, phenyl, halophenyl, C.sub.1-4 alkyl, C.sub.1-4 l carbalkoxy or --(CH.sub.2).sub.n OH where n is 2 or 3; and wherein the thiophene ring is unsubstituted or is substituted by a C.sub.1-4 alkyl group in the 2-position.
- 16. The formulation of claim 15 wherein the thieno[2,3-b]-[1,5]benzodiazepine is 2-ethyl-7fluoro-10-(4-methyl-1-piperazinyl)-4H-thieno[2,3-b][1,5]benzodiazepine.
- 17. The formulation of claim 15 wherein the thieno[2,3-b][1,5]benzodiazepine is 2-ethyl-7-chloro-10-(4-methyl-1-piperazinyl)-4H-thieno[2,3-b][1,5]benzodiazepine.
- 18. The formulation of claim 15 wherein the thieno[2,3-b][1,5]benzodiazepine is 2-ethyl-7-trifluoromethyl-10-(4-methyl-1-piperazinyl)-4H-thieno[2,3-b][1,5]benzodiazepine.
- 19. The formulation of claim 15 wherein the thieno[2,3-b][1,5]benzodiazepine is 2-ethyl-7-fluoro-10-(1-piperazinyl)-4H-thieno[2,3-b][1,5benzodiazepine.
- 20. The formulation of claim 15 wherein the thieno[2,3-b][1,5benzodiazepine is 2-methyl-7fluoro-10-(4-methyl-1-piperazinyl)-4H-thieno[2,3-b[]1,5]benzodiazepine.
- 21. The formulation of claim 15 wherein the thieno[2,3-b][1,5]benzodiazepine is 2-isopropyl-7-fluoro-10-(4-methyl-1-piperazinyl)-4H-thieno[2,3-b][1,5]benzodiazepine.
Priority Claims (1)
Number |
Date |
Country |
Kind |
51240/74 |
Nov 1974 |
GBX |
|
Parent Case Info
This is a continuation of Ser. No. 633,895 filed Nov. 20, 1975 now abandoned.
US Referenced Citations (3)
Number |
Name |
Date |
Kind |
3474099 |
Renz et al. |
Oct 1969 |
|
3813395 |
Nakanishi et al. |
May 1974 |
|
3985750 |
Protiva et al. |
Oct 1976 |
|
Foreign Referenced Citations (1)
Number |
Date |
Country |
980,853 |
Jan 1965 |
GBX |
Continuations (1)
|
Number |
Date |
Country |
Parent |
633895 |
Nov 1975 |
|